Navigation Links
Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda(R) have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8.

Two of the abstracts include data from the XeNA (Xeloda in NeoAdjuvant) trial, a study of Xeloda and docetaxel with or without Herceptin in patients with invasive breast cancer. The third presentation highlights findings that validate efficacy and cost benefits of Xeloda in breast cancer patients.

-- Poster No. A54, [General Poster Session A, Sept. 7, 12:00 - 12:45

p.m.], "Frequency of circulating tumor cells (CTCs) in an open-label

study of neoadjuvant capecitabine, docetaxel and trastuzumab (CDT)

combination therapy in patients with HER2+ breast cancer (BC)."

(Presenter: Stefan Gluck)

-- Poster No. 100, [General Poster Session C, Sept. 8, 7:00 - 8:00 a.m.],

"Distribution of p53 mutations by AmpliChip assay in patients receiving

neoadjuvant capecitabine (C) plus docetaxel (D) with or without

trastuzumab (T) for newly diagnosed breast cancer (BC)." (Presenter:

Nancy Patten)

-- Poster No. A41, [General Poster Session D, Sept. 8, 11:45 a.m. - 12:45

p.m.], "Capecitabine is associated with fewer adverse events than other

standard therapies in patients with breast cancer: a claims database

analysis." (Presenter: Hope Rugo, M.D.)

These studies affirm Roche's commitment to exploring the expanded use of Xeloda in combination with new therapies.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally occurring protein called thymidine phosphorylase, or TP, Xeloda is transformed into

Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... of the "Europe Fluoroscopy Market - Growth, Trends ... offering. The European market for Fluoroscopy is ... to 2020 Fluoroscopy is used to view ... catheter through blood vessels, bile ducts or the urinary ...
(Date:6/2/2015)... , June 02, 2015 Research and Markets( ... Mammography Market - Growth, Trends And Forecasts (2014 - 2019)" ... market is dominated by the Germany . ... . Developing nations such as Poland ... for mammography equipment can be segmented on the basis of ...
(Date:6/2/2015)... -- Research and Markets ( ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. The delivery of drugs to ... the treatment of neurological disorders. Drugs may be ... (e.g., by intravenous injection) for targeted action in ...
Breaking Medicine Technology:European Fluoroscopy Market Report 2014-2019 - Growth, Trends And Forecasts 2Europe Mammography Market Report 2014-2019 - Growth, Trends And Forecasts 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3
... , WALTHAM, Mass., Dec. 9 Decision Resources, one ... pharmaceutical and healthcare issues, finds that compared to last year,s ... used more often to treat newly diagnosed patients suffering from ... received a TNF-alpha inhibitor versus one year ago (15.2 percent ...
... , NEW ... research report is available in its catalogue: , Medical ... , Fiber optics work on the principle ... an element encased by glass in air of low refractive ...
Cached Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6
(Date:6/2/2015)... Milton Hershey School® graduate Vincent Klomps ’10 ... of the Physician Assistant Program’s entering class of 2015 ... with a white coat, which symbolizes his entrance into ... of Vincent’s accomplishments both at MHS and postgraduation,” said ... of how a top-notch education can lead to achievement ...
(Date:6/2/2015)... MI (PRWEB) June 02, 2015 Erbelli’s ... new website to promote its handmade gourmet pizzas and ... even though the website is new, the recipes are ... since 1995. The main feature of the site is ... appetizing pictures and descriptions of all the items. You ...
(Date:6/2/2015)... June 02, 2015 IMPAK Corporation, ... systems, has announced the availability of “child-resistant” pouches ... poisons by children, especially curious toddlers. The Child ... and tested to CFR 1700.20 protocols. The announcement ... , Looks Like Candy, “With the proliferation of ...
(Date:6/2/2015)... Acara Partners has seen a spike in ... mobile devices, as is now required by recent Google search ... well as several new clients in the medical aesthetics vertical, ... them to meet Google’s new requirements,” commented Fran Acunzo, CEO ... clients in education, non-profits, and the business world.” , ...
(Date:6/2/2015)... DiaTech Oncology, provider of CorrectChemo®, ... to help oncologists provide personalized cancer treatment, has ... (CAP) for its laboratories in the U.S. and ... to the ‘Good Housekeeping’ seal of approval,” says ... for DiaTech. “It’s a rigorous inspection that confirms ...
Breaking Medicine News(10 mins):Health News:Erbelli’s of Bradenton Launches New Mobile-Friendly Website 2Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2Health News:Acara Partners Expands Website and Digital Offerings 2Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2
... BUFFALO, N.Y. -- The University at Buffalo announced today a ... and family to establish the Jacobs Institute, which will support ... of heart and vascular diseases. , ... was made in honor of Lawrence D. Jacobs, M.D., a ...
... 13 Market competition is,mounting to win ... most highly,qualified clinical investigators. Companies that develop ... their studies win an advantage in,bringing their ... white paper "Recruiting and Retaining,High-Quality Clinical Investigators" ...
... for recent disasters, WASHINGTON, June 13 The ... with relief efforts for,the victims of flooding and tornadoes ... West Virginia, the Red Cross is present,with vast amounts ... of,thousands of meals., Already, more than 1,400 Red ...
... Long and costly product,development cycles make it essential ... to the development of compounds with,the greatest potential ... and earlier into the new product process in ... development cycle,time, focus resources for greatest impact and ...
... lead to diagnostic urine test for 10% of men with ... traits of an aggressive type of prostate cancer that occurs ... been identified in hopes of finding a way to diagnose ... the Michigan Center for Translational Pathology at the University of ...
... June 2008: The TRAF1/C5 locus on chromosome 9 has ... diseases including type 1 diabetes and systemic lupus erythematosus ... 2008, the Annual Congress of the European League Against ... Factor-receptor associated factor 1) and C5 (complement component 5) ...
Cached Medicine News:Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 2Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 3Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 4Health News:American Red Cross Issues Appeal for Disaster Relief Fund 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2Health News:Researchers ID Traits of Aggressive Prostate Cancer 2Health News:Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases 2
... First access to the skull by trepanation. ... performance motor at standard operating pressure: 6 ... coupling. Full manual control by a progressive ... with drilling speed of approx. 800 rpm. ...
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills....
DeMartel (Bailey) Wire Saw Guide, 33 cm - 13, flexible....
Galt Skull Trephine with adjustable centering point and detachable cross-bar handle, 19.0 mm....
Medicine Products: